5-Lipoxygenase pathway, dendritic cells, and adaptive immunity

Journal of Biomedicine and Biotechnology

Volumn 2004, Issue 2, 2004, Pages 99-105

  Hedi, Harizi ^a   Norbert, Gualde ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR; LIPID;

ARACHIDONIC ACID METABOLISM; ASTHMA; AUTOCRINE EFFECT; BIOSYNTHESIS; BONE MARROW CELL; DENDRITIC CELL; HUMAN; IMMUNITY; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MEDIATOR RELEASE; NEUTROPHIL; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; REGULATORY MECHANISM; REVIEW;

SIGANUS;

EID: 4644353432     PISSN: 11107243     EISSN: None     Source Type: Journal    
DOI: 10.1155/S1110724304310041     Document Type: Review

References (63)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983;220(4597):568-575.
2. Brock TG, McNish RW, Coffey MJ, Ojo TC, Phare SM, Peters-Golden M. Effects of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. J Immunol. 1996;156(7):2522-2527.
3. Chensue SW, Kunkel SL. Arachidonic acid metabolism and macrophage activation. Clin Lab Med. 1983;3(4):677-694.
4. Ramos BF, Zhang Y, Qureshi R, Jakschik BA. Mast cells are critical for the production of leukotrienes responsible for neutrophil recruitment in immune complex-induced peritonitis in mice. J Immunol. 1991;147(5):1636-1641.
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-252.
6. 4 production from dendritic cells via an IL-10-dependent mechanism. J Immunol 2003;170(1):139-146.
7. Harizi H, Gualde N. Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells. Prostaglandins Leukot Essent Fatty Acids. 2002;66(5-6):459-466.
8. + hematopoietic progenitors and in lymphoid organs. Blood. 2000;96(12):3857-3865.
9. Spanbroek R, Stark HJ, Janssen-Timmen U, et al. 5-Lipoxygenase expression in Langerhans cells of normal human epidermis. Proc Natl Acad Sci USA. 1998;95(2):663-668.
10. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997;387(6633):620-624.
11. Lynch KR, O'Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399(6738):789-793.
12. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255-281.
13. Funk CD. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta. 1996;1304(1):65-84.
14. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294(5548): 1871-1875.
15. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323(10):645-655.
16. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 2001;487(3):323-326.
17. Rouzer CA, Shimizu T, Samuelsson B. On the nature of the 5-lipoxygenase reaction in human leukocytes: characterization of a membrane-associated stimulatory factor. Proc Natl Acad Sci USA. 1985;82(22):7505-7509.
18. Chen XS, Funk CD. The N-terminal "beta-barrel" domain of 5-lipoxygenase is essential for nuclear membrane translocation. J Biol Chem. 2001;276(1):811-818.
19. Radmark O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. 2002;68-69:211-234.
20. Mancini JA, Abramovitz M, Cox ME, et al. 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 1993;318(3):277-281.
21. Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase- activating protein for leukotriene synthesis. Nature. 1990;343(6255):282-284.
22. Jakobsson PJ, Steinhilber D, Odlander B, Radmark O, Claesson HE, Samuelsson B. On the expression and regulation of 5-lipoxygenase in human lymphocytes. Proc Natl Acad Sci USA. 1992;89(8):3521-3525.
23. Gronert K, Clish CB, Romano M, Serhan CN. Transcellular regulation of eicosanoid biosynthesis. Methods Mol Biol. 1999;120:119-144.
24. Radmark O, Shimizu T, Jornvall H, Samuelsson B. Leukotriene A4 hydrolase in human leukocytes. Purification and properties. J Biol Chem. 1984;259(20):12339-12345.
25. Yoshimoto T, Soberman RJ, Spur B, Austen KF. Properties of highly purified leukotriene C4 synthase of guinea pig lung. J Clin Invest. 1988;81(3):866-871.
26. 4 pathway to inflammation control. Nature. 1996;384(6604):39-43.
27. 4 receptor gene. J Exp Med. 2000;192(3):413-420.
28. 4 receptor, BLT2. J Biol Chem. 2001;276(15):12454-12459.
29. 4 receptor. J Biol Chem. 2000;275(35):27000-27004.
30. Christie PE, Henderson WR Jr. Lipid inflammatory mediators: leukotrienes, prostaglandins, platelet-activating factor. Clin Allergy Immunol. 2002;16:233-254.
31. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med. 1994;121(9):684-697.
32. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J Clin Invest. 1999;104(3):309-316.
33. 4 and regulation of vascular and inflammatory responses. Am J Pathol. 2001;158(1):3-9.
34. Nicosia S, Capra V, Accomazzo AR, et al. Receptors and second messengers for Cys-leukotrienes. In: Folco GC, Samuelsson B, Maclouf JA, Velo GP, Eds. Eicosanoids: From Biotechnology to Therapeutic Applications. New York:Plenum Press; 1996: 127-136.
35. Goetzl EJ, An S, Smith WL. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J. 1995;9(11):1051-1058.
36. Bailie MB, Standiford TJ, Laichalk LL, Coffey MJ, Stricter R, Peters-Golden M. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J Immunol. 1996;157(12):5221-5224.
37. Steinhilber D. 5-Lipoxygenase: enzyme expression and regulation of activity. Pharm Acta Helv. 1994;69(1):3-14.
38. Bennett CF, Chiang MY, Monia BP, Crooke ST. Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein, expression in HL-60 cells. Biochem J. 1993;289(pt 1):33-39.
39. Nassar GM, Montero A, Fukunaga M, Badr KF. Contrasting effects of proinflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes. Kidney Int. 1997;51(5):1520-1528.
40. Flamand N, Surette ME, Picard S, Bourgoin S, Borgeat P. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol. 2002;62(2):250-256.
41. Peters-Golden M, Brock TG. Intracellular compartmentalization of leukotriene biosynthesis. Am J Respir Crit Care Med. 2000;161(pt 2)36-40.
42. 4 synthase expression by interleukin 4. J Exp Med. 2001;193(1):123-133.
43. 4 synthesis accompanies adherence-dependent nuclear import of 5-lipoxygenase in human blood eosinophils. J Immunol. 1999;162(3):1669-1676.
44. Coffey MJ, Phare SM, Peters-Golden M. Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. J Immunol. 2000;165(7):3592-3598.
45. Ford-Hutchinson, AW, Bray, MA, Doig, MV, Shipley, ME, Smith, MJ. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature. 1980;286:264-265.
46. Goetzl EJ. Selective feed-back inhibition of the 5-lipoxygenation of arachidonic acid in human T-lymphocytes. Biochem Biophys Res Commun. 1981;101(2):344-350.
47. 4. J Clin Invest. 1986;77(4):1244-1250.
48. 4 induces human suppressor lymphocytes. Biochem Biophys Res Commun. 1982;108(4):1531-1537.
49. 4. J Immunol. 1983;131(2):551-553.
50. 4. Proc Natl Acad Sci USA. 1984;81(11):3501-3505.
51. + lymphocyte phenotype and immunoregulatory functions. J Immunol. 1985;135(2):1357-1360.
52. Rola-Pleszczynski M, Lemaire I. Leukotrienes augment interleukin 1 production by human monocytes. J Immunol. 1985;135(6):3958-3961.
53. 4 in human lymphocyte cultures. Prostaglandins Leukot Med. 1986;23(2-3):207-210.
54. 4 mediated by enhanced effector-target cell binding and increased lytic efficiency. Cell Immunol. 1987;110(2):243-252.
55. Rola-Pleszczynski M, Gagnon L, Sirois P. Leukotriene 64 augments human natural cytotoxic cell activity. Biochem Biophys Res Commun. 1983;113(2):531-537.
56. 4. Int J Biochem Cell Biol. 1998;30(2):173-178.
57. 4 receptor subtypes. J Leukoc Biol. 2003;73(6):756-763.
58. Gualde N, Atluru D, Goodwin JS. Effect of lipoxygenase metabolites of arachidonic acid on proliferation of human T cells and T cell subsets. J Immunol. 1985;134(2):1125-1129.
59. 4. Am Rev Respir Dis. 1989;139(5):1257-1264.
60. 4 stimulates human polymorphonuclear leukocytes to synthesize and release interleukin-8 in vitro. Am J Respir Cell Mol Biol. 1994;10(6):651-657.
61. 4 enhances interleukin-6 (IL-6) production and IL-6 messenger RNA accumulation in human monocytes in vitro: transcriptional and posttranscriptional mechanisms. Blood. 1992;80(4):1004-1011.
62. Machida I, Matsuse H, Kondo Y, et al. Cysteinyl leukotrienes regulate dendritic cell functions in a murine model of asthma. J Immunol. 2004;172(3):1833-1838.
63. 4 transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell. 2000;103(5):757-768.